Used primarily in pharmaceutical research, this compound is a key intermediate in the development of targeted cancer therapies. It plays a role in the synthesis of proteolysis-targeting chimeras (PROTACs), which are designed to degrade specific disease-causing proteins. Its structure allows it to bind effectively to both the target protein and the E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of the target. This mechanism is particularly valuable in treating cancers driven by proteins that are difficult to inhibit with traditional small molecules. Additionally, it is explored for its potential in treating neurodegenerative diseases by targeting misfolded proteins.